
## Suparno Chakrabarti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7967292/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impact of adaptive natural killer cells, KLRC2 genotype and cytomegalovirus reactivation on late mortality in patients with severe COVIDâ€19 lung disease. Clinical and Translational Immunology, 2022, 11, e1359.	1.7	11
2	Impact of an Immune Modulator Mycobacterium-w on Adaptive Natural Killer Cells and Protection Against COVID-19. Frontiers in Immunology, 2022, 13, .	2.2	5
3	CTLA4Ig-primed donor lymphocyte infusions following haploidentical transplantation improve outcome with a distinct pattern of early immune reconstitution as compared to conventional donor lymphocyte infusions in advanced hematological malignancies. Bone Marrow Transplantation, 2021, 56. 185-194.	1.3	7
4	Safety and efficacy of Sofosbuvir and Velpatasvir in children with active hepatitis C virus infection undergoing haploidentical transplantation. Transplant Infectious Disease, 2021, 23, e13490.	0.7	5
5	Early and Sustained Expansion of Adaptive Natural Killer Cells Following Haploidentical Transplantation and CTLA4Ig-Primed Donor Lymphocyte Infusions Dissociate Graft-versus-Leukemia and Graft-versus-Host Effects. Transplantation and Cellular Therapy, 2021, 27, 144-151.	0.6	12
6	Haploidentical Transplantation: Challenges and Solutions. Organ and Tissue Transplantation, 2021, , 223-263.	0.0	0
7	A Cohort Comparison Study Evaluating the Role of Protective Foot-wear in Intensive Care Unit. Acta Scientific Medical Sciences, 2021, 4, 33-38.	0.0	Ο
8	CTLA4IG (Abatacept) Based Haploidentical HCT Along with Post-Transplant Cyclophosphamide and Sirolimus for Non-Malignant Disorders in Children: Long-Term Follow-up and Quality of Life. Transplantation and Cellular Therapy, 2021, 27, S391-S392.	0.6	0
9	Species Level Identification of Yeast and Yeast Like Fungus for Prompt Infection Control Measures in Prevention of Outbreaks: With Special Reference to Candida auris in Pre-covid Era. Acta Scientific Microbiology, 2021, 4, 19-25.	0.0	0
10	CTLA4Ig-based T-cell costimulation blockade is associated with reduction of adenovirus viremia following post-transplantation cyclophosphamide-based haploidentical transplantation. Bone Marrow Transplantation, 2020, 55, 649-652.	1.3	9
11	CTLA4Ig Limits Both Incidence and Severity of Early Cytokine Release Syndrome following Haploidentical Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, e86-e87.	2.0	0
12	Alterations in NKG2A and NKG2C Subsets of Natural Killer Cells Following Epstein–Barr Virus Reactivation in CTLA4lg-based Haploidentical Transplantation Is Associated With Increased Chronic Graft-Versus-Host Disease. Transplantation, 2020, 104, e23-e30.	0.5	22
13	Extended Infusion of Prophylactic Mesna Along with CTLA4Ig in Post-Transplantation Cyclophosphamide Based-Haploidentical Transplantation Is Associated with Reduced Incidence of BK Viruria and Hemorrhagic Cystitis. Biology of Blood and Marrow Transplantation, 2020, 26, S142.	2.0	0
14	Focusing On A Unique Innate Memory Cell Population Of Natural Killer Cells In The Fight Against COVID-19: Harnessing The Ubiquity Of Cytomegalovirus Exposure. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020047.	0.5	12
15	Prophylactic oseltamivir during major seasonal influenza H1N1 outbreak might reduce both H1N1 and associated pulmonary aspergillosis in children undergoing haploidentical transplantation. Transplant Infectious Disease, 2020, 22, e13309.	0.7	4
16	CTLA4Ig in an Extended Schedule along with Sirolimus Improves Outcome with a Distinct Pattern of Immune Reconstitution Following Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation for Hemoglobinopathies. Biology of Blood and Marrow Transplantation, 2020, 26, 1469-1476.	2.0	14
17	NKG2C+NKG2A-CD56dim Subset of NK Cells Show Increased Anti-Leukemia Potential in Presence of CTLA4lg in-Vitro and Is the Key Determinant of Early Relapse and Long-Term Disease-Free Survival without Gvhd Following CTLA4lg-DLI Based Haploidentical HCT. Biology of Blood and Marrow Transplantation. 2020. 26. S62.	2.0	0
18	Impact of extended infusional mesna prophylaxis on the incidence of BK viruria and hemorrhagic cystitis following post-transplantation cyclophosphamide and CTLA4Ig-based haploidentical transplantation, Annals of Hematology, 2020, 99, 839-845.	0.8	12

#	Article	IF	CITATIONS
19	Haploidentical Transplantation: Challenges and Solutions. Organ and Tissue Transplantation, 2020, , 1-41.	0.0	0
20	Rotavirus infection following postâ€ŧransplantation cyclophosphamide based haploidentical hematopoietic cell transplantation in children is associated with hemophagocytic syndrome and high mortality. Transplant Infectious Disease, 2019, 21, e13136.	0.7	1
21	CTLA4Ig-based reduced intensity conditioning and donor lymphocyte infusions for haploidentical transplantation in refractory aggressive B-cell lymphoma relapsing after an autograft: Early results from a pilot study. Experimental Hematology, 2019, 77, 26-35.e1.	0.2	9
22	Allogeneic Hematopoietic Stem Cell Transplantation for Myeloma: Time for an Obituary or Not Just Yet!. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 416-422.	0.3	3
23	Targeting CD28-CD86 Pathway for Refractory Myeloma Through CTLA4Ig-Based Reduced-Intensity Conditioning and Donor Lymphocyte Infusions After Haploidentical Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e430-e435.	0.2	6
24	Impact of Preemptive Granulocyte Infusions During Febrile Neutropenia in Patients Colonized with Carbapenem-Resistant Gram-Negative Bacteria Undergoing Haploidentical Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1621-1628.	2.0	8
25	Early Expansion of CD56dim NKG2Alow with Late Surge and Persistence of CD56dimNKG2AnegNKG2Cbright NK Cells Attenuate Cytomegalovirus (CMV) Replication and Recurrence As Well As Leukemia Relapse Following Haploidentical HSCT with T Cell Co-Stimulation Blockade and Ptcy. Biology of Blood and Marrow Transplantation, 2019, 25, S328.	2.0	6
26	Long Term Maintenance of Hickman Catheter in Methicillin Resistant Staphylococcus Colonized Patients Undergoing Haploidentical HSCT: Results of a Prospective Study. Biology of Blood and Marrow Transplantation, 2019, 25, S434.	2.0	0
27	A Prospective Study on the Impact of Pre-Emptive Granulocyte Infusion (PGI) in Carbapenem-Resistant Gram Negative Bacilli (CRGNB) Colonized Patients Undergoing Haploidentical HSCT. Biology of Blood and Marrow Transplantation, 2019, 25, S74.	2.0	0
28	Natural killer cell-based immunotherapy with CTLA4Ig-primed donor lymphocytes following haploidentical transplantation. Immunotherapy, 2019, 11, 1221-1230.	1.0	9
29	CTLA4Ig Primed Donor Lymphocyte Infusion: A Novel Approach to Immunotherapy after Haploidentical Transplantation for Advanced Leukemia. Biology of Blood and Marrow Transplantation, 2019, 25, 673-682.	2.0	21
30	Impact of Single-Dose Plerixafor as an Adjunct to Granulocyte Colony-Stimulating Factor–Based Peripheral Blood Stem Cell Mobilization on the Graft Composition and Outcome for T Cell–Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: A Comparative Study. Biology of Blood and Marrow Transplantation, 2018, 24,	2.0	13
31	CD45RA+ Regulatory T Cells (Tregs) in the Graft is Inversely Related to Donor Age and Impacts Early Alloreactivity and Survival in Younger Patients Undergoing Haploidentical PBSC Transplantation with Post-Transplantation Cyclophosphamide (PTCy). Biology of Blood and Marrow Transplantation, 2018, 24, S88-S89.	2.0	1
32	A Comparative Analysis of Graft Composition and Outcome with the Use of Single Dose Plerixafor as an Adjunct to GCSF Based PBSC Mobilisation for T Replete Haploidentical PBSC Transplantation with Post Transplantation Cyclophosphamide : A Pilot Study. Biology of Blood and Marrow Transplantation, 2018, 24, S207-S208.	2.0	0
33	A Novel Approach Towards Natural Killer Cell Immunotherapy Following Haploidentical Transplantation: CTLA4Ig Primed Donor Lymphocyte Infusions (DLI). Biology of Blood and Marrow Transplantation, 2018, 24, S76-S77.	2.0	0
34	Higher CD45RA+ Regulatory T Cells in the Graft Improves Outcome in Younger Patients Undergoing T Cell–Replete Haploidentical Transplantation: Where Donor Age Matters. Biology of Blood and Marrow Transplantation, 2018, 24, 2025-2033.	2.0	17
35	CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study, Cytotherapy, 2017, 19, 531-542.	0.3	50
36	CD56 Enriched Donor Cell Infusion Following Post-Transplantation Cyclophosphamide and Cyclosporine Alone for Haploidentical PBSCT in Myeloid Malignancies Is Associated with Prompt Reconstitution of Mature NK Cells and Tregs with Reduced Incidence of aGVHD. Biology of Blood and Marrow Transplantation, 2017, 23, S82-S83.	2.0	0

#	Article	IF	CITATIONS
37	T cell costimulation blockade promotes transplantation tolerance in combination with sirolimus and post-transplantation cyclophosphamide for haploidentical transplantation in children with severe aplastic anemia. Transplant Immunology, 2017, 43-44, 54-59.	0.6	42
38	GUT COLONIZATION WITH CARBAPENEM RESISTANT ENTEROBACTERIACEAE ADVERSELY IMPACTS THE OUTCOME IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: RESULTS OF A PROSPECTIVE SURVEILLANCE STUDY. Mediterranean Journal of Hematology and Infectious Diseases, 2017, 10, 2018025.	0.5	32
39	Haploidentical Transplantation in Children with Acute Leukemia: The Unresolved Issues. Advances in Hematology, 2016, 2016, 1-11.	0.6	10
40	Haploidentical Family Donor Transplantation: At the Crossroads of a Changing Paradigm. Advances in Hematology, 2016, 2016, 1-2.	0.6	0
41	Early Donor Lymphocyte Infusion and NK Ligand Mismatched Donor Might Improve the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Following Posttransplantation Cyclophosphamide-Based Haploidentical PBSC Transplantation with Myeloablative Conditioning. Biology of Blood and Marrow Transplantation. 2016. 22. S81-S82.	2.0	1
42	Improved Outcome of Refractory/Relapsed Acute Myeloid Leukemia after Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation with Myeloablative Conditioning and Early Prophylactic Granulocyte Colony-Stimulating Factor–Mobilized Donor Lymphocyte Infusions. Biology of Blood and Marrow Transplantation, 2016, 22, 1867-1873.	2.0	62
43	T cell costimulation blockade for hyperacute steroid refractory graft versus-host disease in children undergoing haploidentical transplantation. Transplant Immunology, 2016, 39, 46-51.	0.6	17
44	Haploidentical transplantation in children with unmanipulated peripheral blood stem cell graft: The need to look beyond postâ€ŧransplantation cyclophosphamide in younger children. Pediatric Transplantation, 2016, 20, 675-682.	0.5	26
45	Hemophagocytic syndrome following haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide. International Journal of Hematology, 2016, 103, 234-242.	0.7	23
46	Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Children with Advanced Acute Leukemia with Fludarabine-, Busulfan-, and Melphalan-Based Conditioning. Biology of Blood and Marrow Transplantation, 2016, 22, 499-504.	2.0	60
47	Haploidentical Transplantation with PBSC Graft in Children: The Need to Look Beyond Post-Transplantation Cyclophosphamide in Younger Children. Biology of Blood and Marrow Transplantation, 2016, 22, S250.	2.0	0
48	Gut Colonization with Carbapenem Resistant Enterobactriaceae (CRE) Adversely Impacts the Outcome in Patients with Hematological Malignancies: Results of a Prospective Surveillance Study. Blood, 2016, 128, 2402-2402.	0.6	1
49	Developing a Haploidentical Transplant Program: An Indian Experience. Biology of Blood and Marrow Transplantation, 2015, 21, S66.	2.0	1
50	Pretransplant Sirolimus Improves Outcome of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Patients with Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2015, 21, S159.	2.0	1
51	Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Primary Refractory Acute Myeloid Leukemia. Blood, 2015, 126, 4411-4411.	0.6	1
52	Sirolimus as long-term graft-versus-host-disease prophylaxis in haploidentical hematopoietic stem cell transplant recipients for non-malignant disorders is associated with high incidence of acneiform lesions. Indian Journal of Dermatology, 2015, 60, 588.	0.1	0
53	Paternal bone marrow infusion as salvage therapy for severe GVHD following maternal haploidentical transplantation resulting in biparental chimerism. International Journal of Hematology, 2013, 98, 504-508.	0.7	6
54	Contrasting Patterns of Alloreactivity Amongst Malignant and Nonmalignant Diseases Receiving Haploidentical PBSC GRAFT and Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2013, 19, S346.	2.0	3

SUPARNO CHAKRABARTI

#	Article	IF	CITATIONS
55	When matched family donor is not available for blood and marrow transplantation—the Indian dilemma. Apollo Medicine, 2012, 9, 62-67.	0.0	0
56	Usefulness and limitations of Bayesian network model as a mortality risk assessment tool in sickle cell anemia. American Journal of Hematology, 2009, 84, 312-313.	2.0	16
57	EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning. Leukemia and Lymphoma, 2007, 48, 256-269.	0.6	61
58	Adenovirus Infections after Hematopoietic Stem Cell Transplantation: Still Unravelling the Story. Clinical Infectious Diseases, 2007, 45, 966-968.	2.9	13
59	Reduced-Intensity Transplantation in the Treatment of Haematological Malignancies: Current Status and Future-Prospects. Current Stem Cell Research and Therapy, 2007, 2, 163-188.	0.6	7
60	Adenovirus Infections in Stem Cell Transplant Recipients: Recent Developments in Understanding of Pathogenesis, Diagnosis and Management. Leukemia and Lymphoma, 2004, 45, 873-885.	0.6	90
61	Outcome of single fraction total body irradiation-conditioned stem cell transplantation in younger children with malignant disease Comparison with a busulphan-cyclophosphamide regimen. Acta Oncológica, 2004, 43, 196-203.	0.8	14
62	Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. Biology of Blood and Marrow Transplantation, 2004, 10, 186-194.	2.0	93
63	T-cell depletion with Campath-1H  in the bag' for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. British Journal of Haematology, 2003, 121, 109-118.	1.2	54
64	Reconstitution of the Epstein-Barr virus–specific cytotoxic T-lymphocyte response following T-cell–depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood, 2003, 102, 839-842.	0.6	61
65	High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood, 2002, 99, 4357-4363.	0.6	349
66	Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood, 2002, 99, 1071-1078.	0.6	333
67	Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood, 2002, 100, 1619-1627.	0.6	401
68	Critical Factors in Optimizing Graft-Versus-Leukemia Effect for Relapsed Leukemias. Journal of Clinical Oncology, 2002, 20, 2756-2757.	0.8	4
69	Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. British Journal of Haematology, 2002, 119, 1125-1132.	1.2	74
70	The place of rituximab in the treatment algorithm for post-stem cell transplant autoimmune hemolytic anemia. Haematologica, 2002, 87, ELT23.	1.7	3
71	WILL MIXED CHIMERISM CURE AUTOIMMUNE DISEASES AFTER A NONMYELOABLATIVE STEM CELL TRANSPLANT?. Transplantation, 2001, 72, 340-342.	0.5	31
72	RESPIRATORY VIRUS INFECTIONS IN ADULT T CELL-DEPLETED TRANSPLANT RECIPIENTS: THE ROLE OF CELLULAR IMMUNITY. Transplantation, 2001, 72, 1460-1463.	0.5	35

#	Article	IF	CITATIONS
73	Resistance to Antiviral Drugs in Herpes Simplex Virus Infections among Allogeneic Stem Cell Transplant Recipients: Risk Factors and Prognostic Significance. Journal of Infectious Diseases, 2000, 181, 2055-2058.	1.9	115
74	Low dose bolus aminocaproic acid: an alternative to platelet transfusion in thrombocytopenia?. European Journal of Haematology, 1998, 60, 313-314.	1.1	12